Patent intelligence · US
US 8946444
Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
Patent details — US 8946444
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 3, 2015
- Expiration
- Jan 29, 2035
- Applicant
- PTC THERAPEUTICS, INC.
- Claims
- 12
- CPC classes
- A61K, A61K31/343, A61K31/403, A61K31/4035
Quick answer
US 8946444 (Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Feb 3, 2015. Expires Jan 29, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/343, A61K31/403, A61K31/4035, A61K31/407, A61K31/4162
More from PTC THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12398140
Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
granted -
US 12384789
Compounds for treating Huntington's disease
granted -
US 12384797
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
granted -
US 12281083
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
granted -
US 12139499
Heteroaryl compounds for treating Huntington's disease
granted -
US 12103926
Compounds for treating huntington's disease
granted -
US 12023335
Method for treating pancreatic cancer
granted -
US 11938101
Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted
Frequently asked questions
What is US patent 8946444?
US 8946444 (Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Feb 3, 2015. Expires Jan 29, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8946444?
PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.
When does US 8946444 expire?
Our index shows an expiration date of Jan 29, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.